Fig. 8.

Composite efficacy and safety of different doses of rivaroxaban compared with placebo, both combined with standard antiplatelet therapy, for the prevention of recurrent events in patients with ACS in a phase II dose-finding study [76]. Clinically relevant bleeding was the composite of major and non-major clinically relevant bleeding. The composite outcome depicted here was not a pre-defined endpoint of this trial. ACS acute coronary syndrome, bid twice daily, od once daily